Over 90% of human pancreatic cancers have KRAS mutations and pancreas-specific KrasG12D expression in Ptf1aCre/+ (ref. 32); KrasLSL-G12D/+ (ref. 33; PK) mice induces PDAC, albeit after long time periods. Here, KRAS is linked to pancreatic neoplasm.